MYM Appoints New Chief Science Officer
VANCOUVER, British Columbia, March 7, 2018 /PRNewswire/ -- MYM Nutraceuticals Inc., (CSE: MYM) (CSE: MYM.CN) (MYM.CN) (the "Company" or "MYM") is pleased to announce Dr. Charith Adkar has joined MYM as its new Chief Science Officer (CFO) effective immediately.
Dr. Adkar completed his PhD in Plant Biology and Crop Production from the University of Milano, Italy with the specialization in Molecular Plant Pathology. He completed his postdoctoral studies at Hirosaki University, Japan and Universite de Sherbrooke, Canada. His areas of expertise include Plant Science, Biotechnology, Microbiology, Molecular host-pathogen interactions and Bioinformatics.
Dr. Adkar will manage MYM's scientific, research and technological operations. He will work primarily at the Laval and Weedon production facilities.
"We're extremely pleased to welcome Dr. Charith Adkar to the MYM team," said Rob Gietl, CEO of MYM. "Dr. Adkar will be instrumental in leading MYM to be a global innovator in the science and technology of medicinal cannabis. His proven track record and research in plant biology and crop production will ensure that MYM will be on the cutting edge of cannabis plant discovery and research."
Subject to the terms of the Company's stock option plan Dr. Adkar will received 75,000 options to purchase common shares of the company priced at $3.18. The options will vest as follows: 25,000 of the Stock Options will vest on the six (6) month anniversary of the Start Date; 25,000 of the Stock Options will vest on the twelve (12) month anniversary of the Start Date; and 25,000 of the Stock Options will vest on the eighteen (18) month anniversary of the Start Date. The options will expire (1) year after each vesting date.